Below is a detailed overview of the most compelling findings Saxenda (Liraglutide): Proven for Moderate Weight Loss Saxenda, one of the earliest GLP-1 agonists approved for obesity treatment, was evaluated in the SCALE Obesity and Prediabetes trial , which followed 3,713 participants over 56 weeks
Without insurance, $149/month at the lowest dose
Pharmacies are responsible for ensuring medications are stored appropriately before dispensing, but patients should verify the expiration date is adequate for their dosing schedule
The major site of expression appears to be in the renin-expressing juxtaglomerular cells (8)
Be prepared to modify or stop if nausea becomes significant
This jargon just means that it is an agent that acts just like a substance that our body produces, called GLP-1